Skip to main content

Table 2 S-IGF-I for patients included by etiology, stroke subtype and severity, respectively

From: Altered levels of circulating insulin-like growth factor I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study

 

Mean

 

Mean

 

Mean

ΔIGF-I

P

Acute IGF-I

P

3-month IGF-I

P

Age

P

(SD)

 

(SD)

 

(SD)

   

Stroke severity (NIHSS†)

 

Dunnett, q1 vs. q2-q5

      

 q1 (mild)

21.6 (42.0)

N/A

162.4 (59.5)

N/A

140.8 (50.0)

N/A

53.1 (12.5)

N/A

 N

82

 

82

 

82

 

82

 

 q2 (minor)

29.0 (51.0)

ns

181.9 (67.0)

ns

152.9 (53.1)

ns

55.7 (9.9)

ns

 N

66

 

66

 

66

 

66

 

 q3 (moderate)

20.6 (49.5)

ns

168.1 (63.5)

ns

147.6 (56.0)

ns

54.4 (11.1)

ns

 N

66

 

66

 

66

 

66

 

 q4 (major)

28.3 (72.7)

ns

181.6 (61.8)

ns

153.4 (53.6)

ns

58.4 (9.5)

0.01

 N

73

 

73

 

73

 

73

 

 q5 (severe)

0.58 (58.5)

0.04

171.7 (62.5)

ns

171.2 (63.2)

0.003

54.0 (10.7)

ns

 N

67

 

67

 

67

 

67

 

 Missing (n)

0

 

0

 

0

 

0

 

Subtype (OCSP)

 

Tukey’s crosswise

      

 Lacunar cerebral infarction (LACI)

21.1 (37.0)

0.09-TACI

163.9 (57.4)

ns

142.8 (48.5)

**TACI

56.6 (9.6)

0.05-POCI

 N

113

 

113

 

113

 

113

 

 Partial anterior cerebral infarction (PACI)

18.1 (47.3)

ns

172.8 (67.9)

ns

154.7 (59.5)

ns

55.0 (11.3)

ns

 N

104

 

104

 

104

 

104

 

 Posterior cerebral infarction (POCI)

30.7 (59.4)

**TACI

181.6 (65.4)

ns

150.9 (57.1)

ns

52.7 (12.2)

0.11-TACI

 N

94

 

94

 

94

 

94

0.05-LACI

 Total anterior cerebral infarction (TACI)

−1.5 (68.1)

**POCI

171.7 (58.4)

ns

173.3 (57.1)

**LACI

52.7 (9.3)

0.11-POCI

 N

37

0.09-LACI

37

 

37

 

37

 

 Missing (N)

6

 

6

 

6

 

6

 

Etiology (TOAST)

 

Tukey’s crosswise

      

 Large vessel diseaase (LVD)

20.4 (53.7)

ns

181.1 (57.0)

*D

160.8 (57.9)

ns

59.0 (7.8)

***D, **Cr

 N

51

 

51

0.08-CE

51

 

51

 

 Small vessel diseaase (SVD)

19.1 (39.6)

ns

161.4 (60.6)

***D

142.3 (53.4)

**D

58.4 (7.2)

***D, **Cr

 N

69

 

69

 

69

 

69

 

 Cardioembolic (CE)

6.1 (46.2)

ns

151.2 (53.3)

***D, 0.08-LVD

145.1 (51.1)

*D

55.5)11.6)

*D

 N

52

 

52

0.15-Cr

52

 

52

 

 Cryptogenic (Cr)

20.1 (43.3)

ns

174.1 (60.7)

***D

154.0 (53.9)

0.09 vs. D

53.1 (11.9)

**LVD/SVD

 N

112

 

112

0.15-CE

112

 

112

 

 Arterial dissection (D)

40.1 (95.7)

*CE

223.7 (63.0)

***SVD/CE/Cr

183.6 (66.7)

**-SVD

48.1 (9.4)

***LVD/SVD

 N

27

 

27

*LVD

27

*CE, 0.09-Cr

27

**Cr, 0.14-D

 Other/undeterrmined

26.2 (45.7)

N/A

172.2 (71.9)

N/A

146.0 (53.7)

N/A

54.2 (13.5)

N/A

 n

43

 

43

 

43

 

43

 

 Missing (N)

0

 

0

 

0

 

0

 
  1. P-values less than 0.3 are specified although they are considered being not signicant (ns). * < 0.05, ** < 0.01. *** < 0.001 for Dunnett’s or Tukey’s post-hoc tests as indicated. As we have a slightly different number of included patients, and using NIHSS instead of SSS as it was presented in 2011, we present s-IGF-I (acute, 3-month) for comparison with the present inclusion (n = 354). TOAST = Trial of Org 10,172 in Acute Stroke Treatment [1], OCSP = Oxfordshire Community Stroke Project [4]. All variation shown is given in standard deviations (SD). N/A designates not applicable. †Scoring of neurological function is taken from the original SSS scores and converted to NIHSS (methods)